{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:46:06Z","timestamp":1759178766434,"version":"3.37.3"},"reference-count":52,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The introduction of direct-acting antiviral agents (DAA) has revolutionized management and care of patients with chronic hepatitis C virus (HCV) infection, leading to cure rates higher than 90% in patients with advanced liver disease as well. Viral eradication has been associated with longer survival, reduced mortality from both hepatic and extrahepatic causes, improvement in liver function, and reduced incidence of HCV-related extrahepatic diseases. While patients with mild fibrosis can safely be discharged after achievement of a sustained virological response, patients with advanced fibrosis and cirrhosis remain at risk of developing complications of liver disease, thus requiring regular and life-long surveillance. Major complications of cirrhosis that need to be monitored are hepatocellular carcinoma onset and development or progression of clinically significant portal hypertension.<\/jats:p>","DOI":"10.1055\/s-0040-1702944","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T23:57:58Z","timestamp":1582847878000},"page":"233-239","source":"Crossref","is-referenced-by-count":6,"title":["Postsustained Virological Response Management in Hepatitis C Patients"],"prefix":"10.1055","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-4876","authenticated-orcid":false,"given":"Chiara","family":"Masetti","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-7902","authenticated-orcid":false,"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-3226","authenticated-orcid":false,"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"M H Lee","year":"2012","journal-title":"J Infect Dis"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection","volume":"166","author":"O Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin","volume":"139","author":"M G Swain","year":"2010","journal-title":"Gastroenterology"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/jvh.12967","article-title":"Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy","volume":"25","author":"K Hayashi","year":"2018","journal-title":"J Viral Hepat"},{"key":"ref8","first-page":"A595","article-title":"Sustained viral response following treatment with direct acting antiviral regimens is durable in more than 6,600 patients: results of the Gilead Sustained Virologic Response Registry Study","volume":"68","author":"C Schwabe","year":"2018","journal-title":"Hepatol"},{"issue":"S 05","key":"ref9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14787210.2019.1588112","article-title":"Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents","volume":"17","author":"L Wei","year":"2019","journal-title":"Expert Rev Ant-Infect Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"H Midgard","year":"2016","journal-title":"J Hepatol"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/QAD.0000000000002103","article-title":"Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV\/hepatitis C virus coinfected individuals","volume":"33","author":"J Berenguer","year":"2019","journal-title":"AIDS"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13240","article-title":"High rates of hepatitis C reinfection following antiviral treatment in the North East England prisons","author":"R Bhandari","year":"2019","journal-title":"J Viral Hepat"},{"issue":"11","key":"ref13","first-page":"629","article-title":"Care of patients following cure of hepatitis C virus infection","volume":"14","author":"N A Terrault","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"A Ciancio","year":"2018","journal-title":"J Med Virol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"S Petta","year":"2018","journal-title":"J Hepatol"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cgh.2018.05.021","article-title":"Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis","volume":"17","author":"P Cacoub","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"F Carrat","year":"2019","journal-title":"Lancet"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"P Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ahj.2017.10.024","article-title":"Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients","volume":"198","author":"P Cacoub","year":"2018","journal-title":"Am Heart J"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/apt.15240","article-title":"The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection","volume":"49","author":"H B El-Serag","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12518","article-title":"The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis","volume":"23","author":"J Peveling-Oberhag","year":"2016","journal-title":"J Viral Hepat"},{"issue":"21","key":"ref22","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"L Arcaini","year":"2016","journal-title":"Blood"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.04.024","article-title":"Long term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure","volume":"155","author":"M Bonacci","year":"2018","journal-title":"Gastroenterology"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cncr.30559","article-title":"Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study","volume":"123","author":"P Mahale","year":"2017","journal-title":"Cancer"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrgastro.2017.172","article-title":"Extrahepatic cancers and chronic HCV infection","volume":"15","author":"S Pol","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"P Nahon","year":"2017","journal-title":"Gastroenterology"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.30034","article-title":"Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication","volume":"68","author":"M Allaire","year":"2018","journal-title":"Hepatology"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease","volume":"68","author":"L I Backus","year":"2018","journal-title":"Hepatology"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2016.01.034","article-title":"Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population","volume":"64","author":"S Bruno","year":"2016","journal-title":"J Hepatol"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.dld.2018.10.014","article-title":"Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals","volume":"51","author":"A Lleo","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"V Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increased risk of de-novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection","volume":"17","author":"E Degasperi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/jvh.12871","article-title":"Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review","volume":"25","author":"A J Walker","year":"2018","journal-title":"J Viral Hepat"},{"issue":"01","key":"ref34","first-page":"43","article-title":"Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct-acting antivirals","volume":"5","author":"K Nguyen","year":"2017","journal-title":"J Clin Transl Hepatol"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jvh.12982","article-title":"Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis","volume":"25","author":"C Masetti","year":"2018","journal-title":"J Viral Hepat"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"F Conti","year":"2016","journal-title":"J Hepatol"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"M Reig","year":"2016","journal-title":"J Hepatol"},{"issue":"05","key":"ref38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral antiviral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"S Lens","year":"2017","journal-title":"Gastroenterology"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jvh.12706","article-title":"Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension","volume":"24","author":"N Afdhal","year":"2017","journal-title":"J Viral Hepat"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stages of portal hypertension","volume":"151","author":"V Di Marco","year":"2016","journal-title":"Gastroenterology"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"R de Franchis","year":"2015","journal-title":"J Hepatol"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy","volume":"156","author":"D Thabut","year":"2019","journal-title":"Gastroenterology"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/j.gastro.2019.02.011","article-title":"The changing scenario of screening and surveillance of esophageal varices","volume":"156","author":"R de Franchis","year":"2019","journal-title":"Gastroenterology"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP3077","article-title":"Why is viral eradication so important in patients with HCV-related cirrhosis?","volume":"22","author":"J Velosa","year":"2017","journal-title":"Antivir Ther"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jgh3.12091","article-title":"Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients","volume":"2","author":"J Romano","year":"2018","journal-title":"JGH Open"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","article-title":"Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort)","volume":"13","author":"I Gentile","year":"2019","journal-title":"Hepatol Int"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"L S Belli","year":"2016","journal-title":"J Hepatol"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","article-title":"The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","volume":"59","author":"R D'Ambrosio","year":"2013","journal-title":"J Hepatol"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"e0155967","DOI":"10.1371\/journal.pone.0155967","article-title":"Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon","volume":"11","author":"R D'Ambrosio","year":"2016","journal-title":"PLoS One"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jhep.2016.08.001","article-title":"Management of the patient with SVR","volume":"65","author":"N A Terrault","year":"2016","journal-title":"J Hepatol"},{"issue":"11","key":"ref51","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","article-title":"Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals","volume":"24","author":"M Noureddin","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/a-0752-0514","article-title":"Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C","volume":"57","author":"S Mauss","year":"2019","journal-title":"Z Gastroenterol"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.hbpd.2018.10.006","article-title":"Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era","volume":"17","author":"M Spadaccini","year":"2018","journal-title":"Hepatobiliary Pancreat Dis Int"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1702944.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T22:36:38Z","timestamp":1599258998000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1702944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":52,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2020,9,4]]},"published-print":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1702944","relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"type":"print","value":"0272-8087"},{"type":"electronic","value":"1098-8971"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}